RAPT Therapeutics, Inc. (RAPT) Accumulated Depreciation & Amortization (2020 - 2024)
RAPT Therapeutics (RAPT) has disclosed Accumulated Depreciation & Amortization for 5 consecutive years, with $9.8 million as the latest value for Q3 2024.
- Quarterly Accumulated Depreciation & Amortization rose 8.04% to $9.8 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $9.8 million through Sep 2024, up 8.04% year-over-year, with the annual reading at $9.4 million for FY2023, 13.55% up from the prior year.
- Accumulated Depreciation & Amortization hit $9.8 million in Q3 2024 for RAPT Therapeutics, up from $9.6 million in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $9.8 million in Q3 2024 to a low of $6.3 million in Q1 2020.
- Historically, Accumulated Depreciation & Amortization has averaged $8.1 million across 5 years, with a median of $7.9 million in 2022.
- Biggest five-year swings in Accumulated Depreciation & Amortization: grew 17.64% in 2021 and later grew 2.18% in 2022.
- Year by year, Accumulated Depreciation & Amortization stood at $7.1 million in 2020, then rose by 8.5% to $7.7 million in 2021, then grew by 7.35% to $8.2 million in 2022, then rose by 13.55% to $9.4 million in 2023, then increased by 4.57% to $9.8 million in 2024.
- Business Quant data shows Accumulated Depreciation & Amortization for RAPT at $9.8 million in Q3 2024, $9.6 million in Q2 2024, and $9.7 million in Q1 2024.